Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting unmet medical needs in oncology and other disease areas. The company combines deep insights into clinically validated biological targets with… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Enliven Therapeutics, Inc. does
In the company’s own words
Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting unmet medical needs in oncology and other disease areas. The company combines deep insights into clinically validated biological targets with differentiated chemistry to design therapies aimed at improving both survival and quality of life for patients.
The company's lead program is ELVN-001, a potent and highly selective small molecule kinase inhibitor designed to target the BCR-ABL gene fusion, the oncogenic driver of chronic myeloid leukemia (CML). ELVN-001 is currently being evaluated in the Phase 1 ENABLE clinical trial in heavily pretreated CML patients, with plans to initiate the Phase 3 ENABLE-2 pivotal trial in the second half of 2026. As of April 2025, the ENABLE trial had enrolled 90 patients across multiple dose levels, with a reported cumulative major molecular response rate of 47% by 24 weeks. ELVN-001 was designed to address limitations of existing therapies, including resistance mutations, off-target adverse effects, drug-drug interactions, and food-related administration requirements.
The company also maintains ELVN-002, a CNS-penetrant and irreversible HER2 inhibitor that has demonstrated clinical activity in HER2-positive and HER2-mutant tumors. In May 2025, Enliven announced it would explore strategic alternatives for ELVN-002 to prioritize ELVN-001 development. Additionally, the company is advancing multiple research-stage programs in areas such as Graves' disease, leveraging its expertise in complex medicinal chemistry and target-agnostic drug discovery approaches.
Enliven was formed through the February 2023 merger of Enliven Inc. and Imara Inc. The company was originally co-founded in 2019 and has assembled a team with extensive experience in small molecule drug discovery, clinical development, and commercialization, including leaders from AbbVie, Amgen, Genentech, Gilead Sciences, and Johnson & Johnson. The company does not operate manufacturing facilities and relies on third-party contract manufacturing organizations for production of its product candidates.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURLINGAME, CA
- Fiscal year end
- December
- CIK
- 1672619
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Enliven Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Enliven Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Enliven Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Enliven Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Enliven Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”